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Abstract
Introduction Cell stimulation leads to the shedding of
phosphatidylserine (PS)-rich microparticles (MPs). Because
autoimmune diseases (AIDs) are characterized by cell
activation, we investigated level of circulating MPs as a possible
biomarker in primary Sjögren's syndrome (pSS), systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA).
Methods We measured plasma levels of total, platelet and
leukocyte MPs by prothrombinase capture assay and flow
cytometry in 43 patients with pSS, 20 with SLE and 24 with RA
and in 44 healthy controls (HCs). Secretory phospholipase A2
(sPLA2) activity was assessed by fluorometry. Soluble CD40
ligand (sCD40L) and soluble P-selectin (sCD62P), reflecting
platelet activation, were measured by ELISA.
Results Patients with pSS showed increased plasma level of
total MPs (mean ± SEM 8.49 ± 1.14 nM PS equivalent (Eq), P
< 0.0001), as did patients with RA (7.23 ± 1.05 n PS Eq, P =
0.004) and SLE (7.3 ± 1.25 nM PS Eq, P  = 0.0004), as
compared with HCs (4.13 ± 0.2 nM PS Eq). Patients with AIDs
all showed increased level of platelet MPs (P < 0.0001), but
only those with pSS showed increased level of leukocyte MPs
(P < 0.0001). Results by capture assay and flow cytometry were
correlated. In patients with high disease activity according to
extra-glandular complications (pSS), DAS28 (RA) or SLEDAI
(SLE) compared with low-activity patients, the MP level was only
slightly increased in comparison with those having a low disease
activity. Platelet MP level was inversely correlated with anti-DNA
antibody level in SLE (r = -0.65; P = 0.003) and serum β2
microglobulin level in pSS (r = -0.37; P < 0.03). The levels of
total and platelet MPs were inversely correlated with sPLA2
activity (r = -0.37, P  = 0.0007; r = -0.36, P  = 0.002,
respectively). sCD40L and sCD62P concentrations were
significantly higher in pSS than in HC (P ≤ 0.006).
Conclusions Plasma MP level is elevated in pSS, as well as in
SLE and RA, and could be used as a biomarker reflecting
systemic cell activation. Level of leukocyte-derived MPs is
increased in pSS only. The MP level is low in case of more
severe AID, probably because of high secretory phospholipase
A2 (sPLA2) activity, which leads to consumption of MPs.
Increase of platelet-derived MPs, sCD40L and sCD62P,
highlights platelet activation in pSS.
AIDs: autoimmune diseases; APLS: anti-phospholipid syndrome; DAS28: Disease Activity Score 28; dsDNA: double stranded DNA; ELISA: enzyme-
linked immunosorbent assay; GPIb: glycoprotein Ib; HC: healthy controls; Ig: immunoglobulin; mAbs: monoclonal antibodies; MGUS: monoclonal 
gammopathy of undetermined significance; MPs: microparticles; PS: phosphatidylserine; pSS: primary Sjogren's syndrome; RA: rheumatoid arthritis; 
sCD40L: soluble CD40 ligand; sCD62P: soluble P-selectin; SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease 
Activity; sPLA2: secretory phospholipase A2; TNF: tumor necrosis factor.Arthritis Research & Therapy    Vol 11 No 5    Sellam et al.
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Introduction
A general feature of activated cells is their ability to shed frag-
ments from their plasma membrane. These fragments repre-
sent a heterogeneous population of small membrane-coated
vesicles with diameter of 0.1 to 1 μm, termed microparticles
(MPs) [1]. MPs belong to the family of circulating vesicles,
including apoptotic bodies and exosomes, and can be
detected in all biological fluids, especially plasma. MPs have to
be differentiated from exosomes and from apoptotic bodies.
Exosomes are smaller than MPs and not generated from the
plasma membrane but arise from the inside of cells in multive-
sicular bodies, and are mostly devoid of phosphatidylserine.
Apoptotic bodies are formed during the final stages of pro-
grammed cell death and are generally larger in diameter and
volume than MPs [1]. The outer layer of the bilayer membrane
of MPs contains aminophospholipids, mainly anionic phos-
phatidylserine (PS), which is procoagulant and detectable by
its binding to annexin V. MPs also contain protein markers spe-
cific to the parental cell types, which allows for the detection
of the cellular origin of MPs [2]. These subcellular structures
can transfer bioactive molecules from parental to target cells,
thus allowing for regulation and amplification of several biolog-
ical mechanisms such as apoptosis or cell activation (inflam-
matory or autoimmune responses, cell proliferation or
coagulation). Hence, MPs could reflect parental cell stimula-
tion and be involved in target cell stimulation [2].
Because of these properties, MPs have been associated with
systemic inflammation or excessive risk of thrombosis in vari-
ous diseases, such as rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), vasculitis and antiphospholipid
syndrome (APLS).
Similar to RA and SLE, primary Sjögren's syndrome (pSS) is
an autoimmune disease (AID) characterized by leukocyte acti-
vation. Platelet activation has been reported in SLE and RA,
but this feature, illustrated by increased level of plasma soluble
CD40 ligand (sCD40L), has been noted only once in pSS
[3,4].
We aimed to assess the plasma level of annexin V-positive
(e.g., PS-positive or total), leukocyte and platelet circulating
MPs in pSS and other AIDs (SLE and RA) as a biomarker of
cell activation.
Materials and methods
Materials and controls
The characteristics of all subjects are shown in Table 1. We
obtained blood samples from 43 patients with pSS fulfilling
American-European Consensus Group criteria [5], 20 with
SLE fulfilling American College of Rheumatology criteria [6]
and 24 with RA fulfilling American College of Rheumatology
criteria [7] in the Department of Rheumatology of Bicêtre Uni-
versity Hospital. The study was approved by the local research
ethics committee, and informed written consent was obtained
from all patients.
Among the 43 pSS patients, extra-glandular involvement as
previously defined [8] was present in 17 patients: lung involve-
ment (n = 3), neurological involvement (n = 4), active synovitis
(n = 2), myositis (n = 2), vasculitis (n = 2), renal involvement (n
= 1), and lymph node enlargement (n = 3). Five patients had
malignant hemopathy, three with marginal zone lymphoma
(one current, two previous) and two current multiple myeloma,
and two had monoclonal gammopathy of undetermined signif-
icance (MGUS). Seven pSS patients received immunosup-
pressive drugs (rituximab, n = 3; rituximab plus methotrexate,
n = 1; cyclophosphamide plus melphalan, n = 1; methotrexate,
n = 2).
For patients with SLE, disease activity was measured by the
SLE Disease Activity Index (SLEDAI) on the day of blood test-
ing [9]. Eleven patients received immunosuppressive drugs
(mycophenolate mofetyl, n = 7; azathioprine, n = 2; rituximab,
n = 2; prednisone >10 mg daily, n = 4). Four patients pre-
sented with a secondary anti-phospholipid syndrome accord-
ing to international criteria [10]. Patients with acute or chronic
infections or with primary anti-phospholipid syndrome were
excluded from the study.
For RA patients, disease activity was measured by the Disease
Activity Score for 28 joints (DAS28) on the day of blood test-
ing. Immunosuppressive agents were given to 19 RA patients
(methotrexate, n = 16; anti-TNFα agents, n = 5; leflunomide, n
= 2); no patient received steroids more than 10 mg daily.
As controls, after informed consent was obtained, we used a
group of 44 healthy controls (HCs) who presented no inflam-
matory, neoplasic, autoimmune or metabolic diseases.
Cardiovascular risk factors (diabetes, smoking, arterial hyper-
tension, hyperlipidemia) were noted in three patients with
pSS, one with SLE, and six with RA. Of note, at the time of
blood testing, no patient or controls presented signs of acute
thrombosis or infection known to modify the plasma level of
MPs.
MP isolation from plasma
According to a standardized procedure [11,12], after collec-
tion of citrated fresh blood samples, MPs were isolated by
double centrifugation at 1500 g for 15 minutes and 13,000 g
for 2 minutes at room temperature and immediately stored at -
80°C for further analysis. This procedure has been previously
validated as mainly yielding MPs and excluding larger apop-
totic bodies, eliminated by the two centrifugation steps [12].
An aliquot of plasma obtained before the second centrifuga-
tion was kept for assessment of secretory phospholipase A2Available online http://arthritis-research.com/content/11/5/R156
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(sPLA2) activity and sCD40L and soluble P-selectin
(sCD62P) content.
MP quantification by functional prothrombinase capture 
assay
Circulating MPs were captured onto insolubilized annexin V
and were called total MPs because annexin V-positive MPs
represent the large majority of the MP population. Capture
with monoclonal antibodies (mAbs) (mAb against human
platelet anti-glycoprotein Ib (GPIb) and CD11a) was per-
formed for platelet and leukocyte MP isolation, respectively.
Then quantification of these captured MPs was performed
with a functional prothrombinase assay in which concentra-
tions of purified clotting factors and calcium (factor Xa, factor
Va, prothrombin and CaCl2) were determined to ensure that
PS was the rate-limiting parameter of the generation of
thrombin from prothrombin [11,12]. Thus, thrombin generation
is dependant on the PS content, which is proportional to the
immobilized MPs. Results are expressed as nanomolar PS
equivalent (nM PS Eq) by reference to a standard curve con-
structed with liposomes of known PS concentrations [13]. For
capture by CD11a and GPIb, background values obtained
with irrelevant immunoglobulin (Ig) Gs of corresponding iso-
types were subtracted from those measured with specific
mAbs. Different affinities of MPs for annexin V and mAbs pre-
vent direct comparison or addition between levels of MPs
measured with use of these ligands.
MP quantification by flow cytometry
Flow cytometry experiments were adapted from Combes and
colleagues [14] and Robert and colleagues [15]. All analyses
were performed by use of a fluorescent-activated cell sorter
(FACS; EPICS XL; Beckman Coulter, Roissy, France) and
RXP-software analysis (Beckman Coulter). Forward scatter
and side scatter were set as a logarithmic gain, and Megamix
(Biocytex, Marseille, France), containing a mix of fluorescent
microbeads of various diameters (0.5, 0.9 and 3.0 μm), was
used for initial settings and before each experiment to measure
Table 1
Characteristics of subjects
pSS SLE RA HC
Number of patients 43 20 26 44
Sex, male/female 1/42 1/19 5/21 7/37
Age, median (range) 60 (26-77) 35.5 (26-77) 55 (23-81) 41 (19-65)
Disease duration, median (range) 9 (1-22) 6 (0.5-31) 5.5 (0.5-41) NA
Positive anti-Ro(SSA) Ab, n (%) 32 (74) NA NA NA
Positive anti-La(SSB) Ab, n (%) 17 (39) NA NA NA
Focus score ≥ 1, n (%) 39 (91) NA NA NA
Extraglandular manifestations, n (%) 17 (36) NA NA NA
Positive anti-DNA antibody, n (%) NA 16 (84%) NA NA
Positive anti-CCP antibody, n (%) NA NA 23 (88) NA
Positive rheumatoid factor, n (%) NA NA 24 (92) NA
Malignant hemopathy, n (%) 5 (12) 0 (0) 0 (0) 0 (0)
SLEDAI, median (range) NA 3 (1-12) NA NA
DAS28, median (range) NA NA 4.8 (1.2-6.3) NA
Secondary APLS 0 4 0 NA
ESR (mm), median (range) 22 (4-44) 22 (4-48) 25 (4-104) NA
C-reactive protein (mg/L), median (range) 1.0 (1-11) 1.5 (1-11) 6 (1-106) NA
Fibrinogen (g/L), median (range) 3.2 (2.6-4.5) 3.4 (2.2-4.8) 4.4 (2.4-8.6) 2.9 (1.7-4.5)
Beta2 microglobulin level (mg/L), median (range) 2.4 (1.6-5.6) NA NA NA
Immunosuppressive drug use, n (%) 7 (16) 11 (55) 19 (73) NA
Ab = antibody; APLS = anti-phospholipid syndrome; CCP = cyclic citrullinated peptide; DAS28 = Disease Activity Score for 28 Joints; ESR = 
erythrocyte sedimentation rate; HC = healthy control; NA = not applicable; pSS = primary Sjogren's syndrome; RA = rheumatoid arthritis; SLE = 
systemic lupus erythematosus; SLEDAI = SLE disease activity score.Arthritis Research & Therapy    Vol 11 No 5    Sellam et al.
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MPs, as an internal control. Gates were then set to include
events between 0.5 and 1.0 μm with exclusion of background
corresponding to debris usually present in buffers.
We incubated 40 μL of platelet-free plasma MPs for 30 min-
utes in the dark at room temperature with annexin V-fluores-
cein isothiocyanate (FITC; Beckman Coulter, Roissy, France),
specific antibodies or isotype-matched irrelevant control (10
μL) conjugated with phycoerythrin after gentle shaking, and
400  μL of annexin V buffer (containing calcium ions) or
PBS1X was added before immediate acquisition. Two nega-
tive controls of annexin V ligation were used: MPs incubated
with annexin V in a calcium-free buffer (to prevent annexin V
ligation to PS) or without annexin V in a specific annexin V
buffer to estimate the auto-fluorescence.
MP subpopulations were determined according to the expres-
sion of membrane-specific antigens from platelets and leuko-
cytes by use of anti-CD61 and anti-CD45 mAbs (Beckman
Coulter, Roissy, France), respectively. Staining with isotype-
matched irrelevant mAbs (Beckman Coulter, Roissy, France)
at the same concentration and under the same conditions was
used as a control.
Before acquisition, a known number of 3 μm calibrated
microbeads (Sigma Aldrich, Saint Louis, MO, USA) was
placed in each tube and run concurrently with the MP samples
in the FACS, thus allowing for quantitative determination of
MPs (annexin V-positive or from different origin). The absolute
number of MPs per millimeter plasma was then determined by
counting the proportion of beads and the exact volume of
plasma from which MPs were analyzed. The analysis was
stopped when a fixed number of microbeads (10,000) were
counted. Results are expressed as number of MPs per micro-
liter by the formula N = (MP × beads per tube/volume of
plasma)/number of counted beads.
Measurement of sPLA2 activity and sCD40L and sCD62P 
content in plasma
We assessed the functional activity of sPLA2 because plasma
sPLA2 is able to hydrolyze phospholipids such as PS or phos-
phatidylcholine present in MPs [16]. Plasma sPLA2 activity,
expressed as nanomoles per minute per millilitre (nmol/min per
mL), was measured by selective fluorometric assay as previ-
ously described [17].
Platelet activation was assessed by measurement of sCD40L
and sCD62P concentrations in plasma by use of the human
sCD40L Quantikine kit and a human sCD62P Immunoassay
(R&D Systems, Lille, France), respectively, following the man-
ufacturer's instructions.
Other biological parameters
Anti-Ro/SSA and anti-La/SSB antibodies and IgG anti-dou-
ble-stranded DNA (dsDNA) antibodies were determined by
counter-immunoelectrophoresis  and ELISA, respectively, as
described previously [18]. The serum β2 microglobulin level
was determined by nephelometry (Array 360 system, Beck-
man Coulter, Roissy, France) as previously described [8].
For biological anti-phospholipid investigations, anticardiolipin
and anti-β2GPI antibody levels were assessed by ELISA (Bio-
rad, Marne la Coquette, France and INOVA Diagnostics, San
Diego, CA, USA, respectively).
Other biological tests were performed as routine in the
Departments of Hematology and Biochemistry of our hospital
(leukocyte and platelet counts, fibrinogen and C-reactive pro-
tein levels).
Statistical analysis
Characteristics of patients are expressed as number and per-
centage and median and range. Results for MP levels are
expressed as mean ± standard error of the mean. Compari-
sons of mean MP levels, sPLA2 activity, sCD40L and sCD62P
concentrations between different groups of subjects (inde-
pendent analysis) were analyzed by non-parametric Mann-
Whitney U test. Spearman's rank correlation coefficients were
calculated to investigate the relation between MP counts and
clinical and biological parameters. A P < 0.05 was considered
statistically significant. Statistical analysis involved use of
GraphPad Prism 5 software (GraphPad Software Inc., San
Diego, CA, USA).
Results
Measurement of circulating MPs in pSS and other AIDs 
by capture assay
MPs detectable by capture onto annexin V were measured in
43 pSS, 20 SLE and 26 RA patients and 44 HCs. The level of
total MPs was significantly higher in patients with pSS (8.49 ±
1.14 nM PS Eq), SLE (7.3 ± 1.25 nM PS Eq), and RA (7.23 ±
1.05 nM PS Eq) than in HCs (4.13 ± 0.2, P < 0.004; Table 2,
Figure 1a). This increase involved particularly platelet-derived
MPs (Table 2, Figure 1b). However, pSS, SLE and RA patients
did not differ in level of total or platelet MPs.
The level of leukocyte-derived MPs was higher in patients with
pSS than in HCs (5.78 ± 0.37 versus 3.92 ± 0.21 nM PS Eq,
P < 0.0001), with no difference between HCs and patients
with SLE or RA (3.89 ± 0.4 and 4.28 ± 0.9, P = 0.46 and P =
0.18, respectively; Table 2, Figure 1c). Moreover, the level of
leukocyte-derived MPs in pSS was significantly higher than
that in SLE or RA (P = 0.003 and P = 0.015, respectively; Fig-
ure 1c).
The number of patients with cardiovascular comorbidities was
low, yet after excluding these subjects, the results of statistical
analyses remained unchanged (data not shown). Moreover, in
pSS patients, the MP levels was the same in patients with
hemopathy (lymphoma, multiple myeloma or MGUS; n = 7)Available online http://arthritis-research.com/content/11/5/R156
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and the others (n = 36; total MPs: 8.6 ± 1.3 vs 7,8 ± 2, P =
0.93). Likewise, MPs level was not different in SLE patients
with (n = 4) or without secondary APLS (n = 16; total MPs: 7.7
± 1.3 vs 5.5 ± 1.2, P = 0.48).
Of note, the level of leukocyte-derived MPs and absolute leu-
kocyte count were not correlated, nor was the level of platelet
MPs and platelet count in each group of patients correlated
(data not shown).
Flow cytometry measurement of circulating MPs
We assessed the plasma levels of total, leukocyte and platelet
MPs by concomitant capture assay and flow cytometry in 17,
8 and 15 subjects, respectively. Results are in Table 2, and a
Figure 1
Plasma level of circulating microparticles Plasma level of circulating microparticles. (a) Total microparticles (MPs); (b) platelet-derived MPs; (c) leukocyte-derived MPs in patients with primary 
Sjögren's syndrome (pSS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and healthy controls (HCs) by solid-phase capture with 
functional prothrombinase assay. Results are expressed as nM PS Eq. Horizontal lines show the mean value. Differences between groups were ana-
lyzed by the Mann-Whitney U test. All comparisons not specified in the figure were not significant (NS).
Table 2
Level of circulating microparticles (MPs), secretory phospholipase A2 (sPLA2), sCD40L, sCD62P in patients with primary Sjögren 
syndrome (pSS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and in healthy controls (HCs)
pSS SLE RA HC
MP level by capture 
assay, nM PS Eq
Total MPs (n) 8.49 ± 1.14 (43) 7.3 ± 1.25 (20) 7.23 ± 1.05 (26) 4.13 ± 0.2 (44)
Platelet GPIb+ MPs (n) 4.89 ± 1.25 (40) 4.28 ± 0.36 (18) 4.86 ± 1.48 (24) 1.12 ± 0.11 (18)
Leukocyte CD11a+ 
MPs (n)
5.78 ± 0.37
(40)
3.89 ± 0.4
(17)
4.28 ± 0.9
(21)
3.92 ± 0.21
(44)
MP number/μL plasma 
by FACS
Total MPs (n) 91,700 ± 31,292 (5) 71,230 ± 19,160 (4) 127,200 ± 46,825 (2) 6422 ± 3472
(5)
Platelet CD61+ MPs (n) 48,930 ± 18,260 (4) 32,290 ± 17,250 (4) 94370 ± 46,584 (2) 4229 ± 3914 (4)
Leukocyte CD45+ MPs 
(n)
927 ± 729
(4)
422 ± 149
(4)
304 ± 33
(2)
190 ± 100
(4)
sPLA2 activity, nmol/min/mL (n) 50.9 ± 3.5
(37)
60.7 ± 8.0
(17)
69.8 ± 9.3
(25)
41.8 ± 3.4
(28)
sCD40L, pg/mL (n) 233 ± 31.7 (33) 262.6 ± 63.9 (17) 345.7 ± 67.23 (25) 133.6 ± 4.8 (33)
sCD62P, ng/mL (n) 38.9 ± 2.5 (34) 39.3 ± 3.7 (16) 43.4 ± 3.0 (25) 23.0 ± 1.0 (32)
Results are expressed as mean ± standard error of the mean. The number of patients tested is indicated in each box (n).Arthritis Research & Therapy    Vol 11 No 5    Sellam et al.
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representative staining is in Figure 2. Results from the two
measurements showed a significant positive correlation for
total MPs (r = 0.72, P = 0.001) as well as for platelet MPs (r
= 0.76, P = 0.04) and for leukocyte MPs (r = 0.54, P = 0.04).
Correlation of MP level with disease activity of pSS and 
other AIDs
As MPs can reflect the state of cellular stimulation, we hypoth-
esized that the level of MPs could be associated with AID
activity. Platelet MP levels were significantly lower in pSS
patients with extra-glandular involvement (3.88 ± 2.3 nM PS
Eq) than in those with only glandular involvement (5.5 ± 1.45
nM PS Eq, P = 0.02) with a similar tendency for total (7.93 ±
2.25 versus 8.86 ± 1.2 nM PS Eq, P = 0.06) and leukocyte
MPs (5.06 ± 0.5 versus 6.25 ± 0.5 nM PS Eq, P = 0.08; Fig-
ure 3).
Serum β2 microglobulin level, a B-cell activation marker asso-
ciated with extra-glandular involvement [8], was inversely cor-
related with level of annexin V-positive MPs (r = -0.48, P =
0.002) and platelet MPs (r = -0.37, P = 0.03; Figures 4a to
4c).
Interestingly, we found similar results for SLE patients: a sig-
nificant negative correlation between level of platelet MPs and
level of anti-double-stranded DNA IgG (r = -0.65, P = 0.003;
Figure 4d) and a negative correlation, although not significant,
between level of platelet MPs and the SLEDAI score (r = -
0.46, P = 0.056). For RA patients, level of leukocyte-derived
MPs and the DAS28 showed a significant negative correlation
(r = -0.6, P = 0.005; Figure 4e).
Patients with AIDs receiving (n = 52) or not receiving (n = 37)
immunosuppressive drugs or biological agents did not differ in
level of MPs (total MPs: 8.4 ± 0.9 vs 7.1 ± 1.0, P = 0.13).
Consumption of MPs by soluble PLA2
We hypothesized that because MPs contain accessible ani-
onic phospholipids such as PS, they could be consumed by
sPLA2. This enzyme is increased in level and activity in some
inflammatory diseases and catalyzes hydrolysis of aminophos-
pholipids, including PS, as well as phosphatidylcholine and
phsophatidylethanolamine, all contained in microvesicles [16].
Plasma sPLA2 activity was significantly higher in patients with
pSS (P = 0.028), SLE (P = 0.036), and RA (P = 0.005) than
in HCs (Table 2). Interestingly, the level of total MPs and activ-
ity of sPLA2 showed a significant inverse correlation for all
patients with AIDs (r = -0.37, P = 0.0007 and r = -0.36, P =
0.002 for total and platelet MPs, respectively; Figure 5). More-
over, sPLA2 activity was significantly higher in the 14 pSS
patients with extra-glandular involvement than in those with
only glandular involvement (56.7 ± 3 versus 47.3 ± 5.2 nM/
min/mL, P = 0.01). Conversely, MP level was not correlated
with level of C-reactive protein, a classical marker of systemic
inflammation.
Increased levels of platelet activation biomarkers 
(sCD40L and sCD62P) in AIDs
As we found increased levels of platelet-derived MPs in the
three studied AIDs and because platelet activation has been
Figure 2
Representative flow cytometry density plots showing the gating proto- col for microparticles Representative flow cytometry density plots showing the gating proto-
col for microparticles. The gate of microparticles (MPs) was defined by 
use of Megamix containing fluorescent latex microbeads (0.5, 0.9 and 3 
μm) (a) Quantitative estimation of MPs involved use of a fixed number 
of 3 μm microbeads, which were counted concomitantly with MP 
acquisition in the specific gate. (b to d) Gated MPs alone (b) without 
annexin V addition, (c) stained with annexin V FITC in a calcium-specific 
buffer, and (d) stained with annexin V in PBS (without calcium). (e) Iso-
type controls, (f) platelet MPs (CD61+), (g) leukocytes MPs (CD45+) 
using a single staining.Available online http://arthritis-research.com/content/11/5/R156
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poorly assessed in pSS, we assessed plasma levels of
sCD40L and sCD62P, two biomarkers of platelet activation
(Table 2). The concentration of sCD40L was significantly
higher in pSS and RA patients than in HCs and higher, but not
significantly, in SLE patients than in HCs (P = 0.006, P <
0.0001 and P = 0.09, respectively). sCD62P levels were sig-
nificantly higher in patients with pSS, RA and SLE than in HCs
(P < 0.0001, P = 0.0003 and P < 0.0001, respectively). We
found no association or correlation of level of these biomarkers
with disease activity.
Discussion
In the present study, we investigated the plasma level of circu-
lating MPs in patients with the AIDs pSS, SLE and RA and
found a higher level of total and platelet-derived circulating
MPs as compared with HCs. A specific feature of pSS was an
elevated level of leukocyte-derived MPs, which was not
observed in other AIDs. Interestingly, in severe pSS with ext-
raglandular manifestations, the level of platelet MP was less
increased than those in pSS patients with glandular involve-
ment only. In addition, we found an inverse correlation
between level of MPs and disease activity in RA and SLE.
Moreover, we found the level of MPs inversely correlated with
two other quantitative biomarkers, serum β2 microglobulin
level in pSS and anti-dsDNA IgG antibodies in SLE.
The patients in our study were slightly older than those in the
HC group. No correlation has been observed between the
total MPs levels and the age of patients in each disease group
(P  > 0.1). Likewise, no data in the literature suggest any
impact of age on MP levels except in subjects younger than 18
years old [19]. The relatively small number of men in each
group may probably not have an impact on MP levels: the com-
parison of the MP levels between men and women with AIDs
has shown no difference according to the sex for each subtype
of MPs (P > 0.16). To avoid the confounding effects of other
factors susceptible to increase the level of MPs, such as car-
diovascular risk factors or infection [20], we verified that asso-
ciated cardiovascular co-morbidities might not have
influenced the increased number of MPs. In addition, we have
not included patients with recent thrombosis, acute or chronic
infection who represent confounding factors disturbing the
interpretation of results in AIDs. Finally, some patients have
very high levels of MPs, suggesting that MP levels may be het-
erogenous in a defined disease group. However, after exclud-
ing patients with total and platelet MP levels above 20 nM PS
Eq and leukocyte MP levels above 10 nM PS Eq in all groups,
the statistical analysis remained unchanged (data not shown).
Circulating MPs originate from cell plasma membranes and
are generated after cell stimulation (apoptosis or activation). In
AIDs, MPs could be released at a systemic level by cytokine
stimulation according to the same mechanism demonstrated
in vitro [14,21,22]. The increase in the level of platelet MPs
suggests that platelets were activated in the three diseases
we studied. To confirm this feature in AIDs, the plasma con-
centrations of sCD40L and sCD62P, which are released by
platelets upon stimulation and considered the two typical
Figure 3
Plasma level of circulating microparticles Plasma level of circulating microparticles. (a) Total microparticles (MPs); (b) platelet-derived MPs; (c) leukocyte-derived MPs in patients with primary 
Sjögren's syndrome (pSS) according to presence or not of extra-glandular involvement and in healthy controls (HCs) by solid-phase capture associ-
ated with functional prothrombinase assay. Results are expressed as nM PS Eq. Solid bars show the mean.Arthritis Research & Therapy    Vol 11 No 5    Sellam et al.
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biomarkers of platelet activation [23], were increased in all AID
groups as compared with HCs. This increase has been
reported for RA and SLE [3,24,25], whereas in pSS, sCD40L
has been reported only once [4], and sCD62P measurement
in pSS has never been assessed. These data emphasize the
known role of platelets in RA and SLE. Of note, activated
platelets in SLE could activate plasmacytoid dendritic cells for
interferon-alpha production [26]. These latter cells are also
detected in labial salivary glands of patients with pSS [27];
hence, platelets could also contribute to plasmacytoid den-
dritic-cell activation in pSS.
As MPs can be detected by several non-standardized meth-
ods [28], we assessed MPs with two different methods simul-
taneously, solid-phase capture assay and flow cytometry, the
results being positively correlated. Of interest, capture assay
detects leukocytes and platelet MPs as being annexin V posi-
tive, whereas quantification of these subtypes of MPs by flow
cytometry does not use annexin V ligation and thus involves
annexin V-positive MPs as well as the small fraction of annexin
V-negative MPs [2]. However, no clinical association with
results obtained on flow cytometry was tested because few
patients were tested with this method. Furthermore, tissue fac-
tor-positive MPs were not assessed in this study because of
the low frequency of thombotic manifestations in pSS.
As MPs are generated after cell activation and/or apoptosis, it
is not possible to discriminate between these two mecha-
nisms to explain the increase in MPs in AIDs. If apoptosis play
a role, it is probably not linked to immunosuppressive agents
because the patients treated with these drugs did not have
higher levels of MPs.
Increased plasma MP levels have been reported in metabolic,
cardiovascular, infectious, neoplastic and autoimmune dis-
eases [29]. In autoimmune diseases, MPs have been found
elevated in RA [3,30], SLE [14,31], Crohn's disease [32], sys-
temic sclerosis [22], vasculitis [33-35] and myositis [36]. Here
we report the first assessment of circulating MPs in pSS. An
interesting finding was the significantly decreased level of
Figure 4
Correlation between serum level of beta 2 microglobulin (mg/L) and plasma level of total microparticles Correlation between serum level of beta 2 microglobulin (mg/L) and plasma level of total microparticles. (a) Platelet-derived microparticles (MPs), 
and (c) leukocyte-derived MPs (nM PS Eq) in primary Sjögren's syndrome (pSS). (d) Correlation between level of IgG anti-double-stranded DNA 
antibody (IU/L) and platelet MPs in SLE patients. (e) Correlation between disease activity score 28 (DAS28) and leukocyte MPs in RA patients.Available online http://arthritis-research.com/content/11/5/R156
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platelet MPs in pSS patients with more severe disease corre-
sponding to extra-glandular involvement compared with those
with glandular involvement only. A similar feature was also
shown in patients with more severe SLE and RA disease as
assessed by the SLEDAI and DAS28, respectively. However,
in the three AIDs, the level of MPs in patients with more severe
disease remained greater than in HCs. In fact, similar results
have been recently reported in systemic sclerosis [22] and
Crohn's disease [32] on assessment of MPs by flow cytometry
and solid-phase capture assay, respectively. These results and
the present results suggest that the level of circulating MPs
might be inversely related to severity of disease as a general
biological mechanism. In RA, discordant results have been
reported: MP level was found increased or not different from
that in HCs [30,37,38]. Finally, for other acute inflammatory
diseases such as severe sepsis or multiple organ dysfunction
syndrome, the number of platelet and endothelial MPs was
found to be lower than that for controls [39] and a low level of
MPs in severe sepsis was associated with a poorer prognosis
[40].
Several hypotheses could explain these discordant findings.
First, the decreased plasma level of MPs could be a result of
consumption or confinement of MPs by adhesion in the tissue
target of the AID such as the synovium in RA [41]. Second,
MPs can aggregate circulating leukocytes and platelets, thus
leading to the formation of leukocyte-platelet complexes. Thus,
MP measurements do not take these MPs sequestered in cell
aggregates into account, which leads to an underestimation of
their amount [3,42]. These aggregates were found in higher
levels in SLE and RA patients than in controls, but no associ-
ation with disease activity has been reported to date [3,25,43].
Finally, the decreased level of MPs in active disease could be
explained by the destruction of circulating MPs in the periph-
eral blood by phospholipases, especially sPLA2, which targets
its aminophospholipid substrates in shedded membrane parti-
cles to generate lysophosphatidic acid [16].
Interestingly, we found a significant inverse correlation
between levels of total MPs or platelet-derived MPs and
sPLA2 activity in patients. We hypothesised that plasma MPs
could be destroyed by increased sPLA2 through the degrada-
tion of their aminophospholipids in active disease. Thus, previ-
ous  in vitro experiments showed that cell-derived
microvesicles provide a preferential substrate for sPLA2 by
the transformation of phospholipids present in MPs into lyso-
phosphatic acid [16]. New experiments assessing a direct
consumption of MPs by sPLA2 would be very interesting to
perform.
sPLA2 activity was increased in all patients, especially pSS
patients with extra-glandular involvement who showed a signif-
icantly decreased level of platelet MPs. Furthermore, although
high level of sPLA2 has been reported in RA [44,45], we
report for the first time in pSS and SLE the increased func-
tional activity of sPLA2, despite the absence of increased lev-
els of other classical biological markers of systemic
inflammation (C-reactive protein and fibrinogen; Table 1).
Thus, the exact role of sPLA2 in AIDs, in addition to its pro-
inflammatory role, remains to be elucidated, especially in the
context of cardiovascular complications observed in these dis-
eases. Of note, we did not use a quantitative but rather a func-
tional assay of sPLA2, which may better explain MP
destruction in case of active disease.
To date, plasma level of MP has been considered a biomarker
reflecting cell activation and could participate in the acceler-
ated atherosclerosis observed in AIDs, but involvement of MPs
in the cross-talk between resident cells in target organs of
autoimmunity and inflammatory infiltrating cells has been
Figure 5
Correlation between plasma activity of secretory phospholipase A2 (sPLA2a) (expressed as nmol/min/mL) and plasma level of circulating (a) total  microparticles (MPs), (b) platelet-derived MPs and (c) leukocyte-derived MPs (nM PS Eq) Correlation between plasma activity of secretory phospholipase A2 (sPLA2a) (expressed as nmol/min/mL) and plasma level of circulating (a) total 
microparticles (MPs), (b) platelet-derived MPs and (c) leukocyte-derived MPs (nM PS Eq).Arthritis Research & Therapy    Vol 11 No 5    Sellam et al.
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sparsely reported. In RA, leukocyte MPs can activate synovial
fibroblasts [21,46,47], but no data are available for pSS and
SLE. Only exosomes, another kind of circulating vesicles con-
taining specific auto-antigens and generated by salivary gland
epithelial cells, have been identified [48]. As we found ele-
vated MP level in pSS, the functional role of MPs remains to
be elucidated, as does the role of platelet activation, despite
the absence of increased thrombosis in this disease.
Conclusions
We demonstrate that the level of circulating MPs is signifi-
cantly elevated in pSS, as well as in RA and SLE, and could
represent a new biomarker reflecting the systemic state of cell
activation in these diseases. However, because the level of
MPs increases less in patients with more severe disease, the
interest of using MP levels for monitoring disease activity is
limited, unless assessment of sPLA2 activity is performed in
parallel. Indeed, a decrease in active disease could be related
to a degradation process of MPs by sPLA2. Additional studies
of function are needed to understand the involvement of MPs
in signalling pathways of remote cellular cross-talk in AIDs and
how platelets are precisely involved in pSS. Finally, investiga-
tion of the production of MPs at a local level in the target
organs of autoimmunity, such as salivary glands in pSS, could
be helpful for better understanding the role of these vesicles
as mediators of the intercellular cross-talk.
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